Wall Street analysts forecast that ResMed (RMD) will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Shares of ResMed Inc. RMD shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Resmed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market ...

Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

EBR Systems, backed by investors such as HESTA, Hostplus and private equity veteran Mark Carnegie, can start selling its technology within months.

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and cloud-connected software for the healthcare sector. With a market cap of $33 ...

ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...